ArticleVaccine2008
Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil.
Article in Vaccine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 67 citations in OpenAlex.
- Leishmaniasis vaccine research: current status and new directions.Parasitology · 2026Review
- Design and development of highly conserved, HLA-promiscuous T cell multiepitope vaccines against human visceral leishmaniasis.Frontiers in immunology · 2025Article
- Advances inPathogens (Basel, Switzerland) · 2024Review
- Combining Killed Vaccine Candidate with Different Adjuvants to Determine Prophylactic Potential against Leishmaniasis.Acta parasitologica · 2024Article
- Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future.The Korean journal of parasitology · 2022Article
- Vaccination in Leishmaniasis: A Review Article.Iranian biomedical journal · 2022Article
- What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.Frontiers in immunology · 2020Article
- The Delay in the Licensing of Protozoal Vaccines: A Comparative History.Frontiers in immunology · 2020Review
- Saponins fromMolecules (Basel, Switzerland) · 2019Review
- Nucleoside Hydrolase NH 36: A Vital Enzyme for theFrontiers in immunology · 2019Review
- The F1F3 Recombinant Chimera ofFrontiers in immunology · 2019Article
- Leishmaniasis in humans: drug or vaccine therapy?Drug design, development and therapy · 2018Review
- Biomarkers Associated WithFrontiers in cellular and infection microbiology · 2018Review
- Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.Medical microbiology and immunology · 2015Article
- Ability of immunodiagnostic tests to differentiate between dogs naturally infected with Leishmania infantum and Leishmune(®)-vaccinated dogs.Veterinary research communications · 2015Article
- One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis.BMC veterinary research · 2015Article
- Article
- Visceral leishmaniasis in Brazil: rationale and concerns related to reservoir control.Revista de saude publica · 2014Article
- Identifying vaccine targets for anti-leishmanial vaccine development.Expert review of vaccines · 2014Review
- LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4⁺ and CD8⁺) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis.Parasites & vectors · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmune is the industrialized version of the FML-saponin vaccine which has been shown to develop 92-95% protection in vaccinated dogs and 76-80% vaccine efficacy against field canine visceral leishmaniasis (CVL) in Brazil. Leishmune has been proven to be safe and tolerable and a transmission-blocking vaccine which renders vaccinated dogs non-infectious to sand fly vectors. In the present investigation, 550 healthy seronegative dogs of endemic and epidemic areas of Brazil were monitored for Leishmune-induced immunogenicity during a 2-year trial. Another group of 588 untreated exposed dogs was also studied in parallel. Both groups were seronegative on day 0. The strong immunogenicity induced by Leishmune vaccine was demonstrated by the 98% of FML-seroconversion, increase in absorbencies, the 82.7% DTH positive reactions and increase in skin test size diameters, the average increase in CD8+ total lymphocytes population in blood (27.1%), expected for QS21 saponin-containing vaccine, the sustained proportions of CD4+ T cells, and the average increased proportions of CD21+ B lymphocytes (42.3%). The Leishmune-induced protection against CVL is demonstrated by the results: 98.8% asymptomatic dogs (at the end of first year) and 99% healthy survivors (at the end of the second year) among vaccinated dogs, compared to the 79.4% asymptomatic and 61% survivor dogs (p<0.001) monitored in the untreated exposed cohort. In spite of the low vaccine coverage, it was possible to detect a 66.1% (p<0.005) reduction in Belo Horizonte and an 80.2% (p<0.005) reduction in Araçatuba of the incidence of CVL among vaccinated dogs, when compared to the global incidence of CVL of each town, respectively. Our preliminary results support the potential use of Leishmune to prevent CVL epidemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.